Abbott Laboratories (NYSE: ABT) has sold the assets of Fournier R&D laboratories, located in Daix, France, to Inventiva, a company created as part of a management buyout. The assets include 12 000 m² of laboratories and equipment and a 230,000 molecule library, and will address four therapeutic targets: Parkinson’s disease, oncology, autoimmune diseases and fibrosis. In addition Abbott has signed a five-year partnership with Inventiva that will finance a large part of the operating costs. EC Mergers & Acquisitions acted as exclusive advisor to Abbott on this transaction.
